<p>Maze Therapeutics, Inc.（纳斯达克代码：MAZE - 获取免费报告）高级副总裁艾米·巴赫罗特于 2 月 2 日星期一出售了 5,000 股该公司的股票。股票以平均价格 46.04 美元出售，总交易额为 230,200.00 美元。交易后，这位高级副总裁直接持有该公司 12,965 股股票，价值 596,908.60 美元。这代表其持股比例下降了 27.83%。该出售在向美国证券交易委员会（SEC）提交的文件中披露，相关文件可通过 SEC 网站访问。</p>
<p>获取 <strong>Maze Therapeutics</strong> 的提醒：</p>
<ul>
<li>生物科技突破：3 只具有巨大上涨潜力的股票</li>
</ul>
<p>艾米·巴赫罗特最近还进行了以下交易：</p>
<ul>
<li>在 1 月 22 日星期四，艾米·巴赫罗特出售了 5,000 股 Maze Therapeutics 的股票。股票以平均价格 45.52 美元出售，总价值为 227,600.00 美元。</li>
<li>在 1 月 2 日星期五，艾米·巴赫罗特出售了 5,000 股 Maze Therapeutics 的股票。股票以平均价格 39.15 美元出售，总价值为 195,750.00 美元。</li>
<li>在 12 月 29 日星期一，艾米·巴赫罗特出售了 10,000 股 Maze Therapeutics 的股票。股票以平均价格 40.58 美元出售，总价值为 405,800.00 美元。</li>
<li>在 12 月 30 日星期二，艾米·巴赫罗特出售了 5,000 股 Maze Therapeutics 的股票。股票以平均价格 40.08 美元出售，总价值为 200,400.00 美元。</li>
</ul>
<h2>Maze Therapeutics 股票上涨 0.4%</h2>
<p>在周三的交易时段，MAZE 的股票上涨了 0.17 美元，达到了 48.14 美元。该公司交易了 588,235 股，相较于其平均交易量 434,867 股。Maze Therapeutics, Inc.的 52 周最低价为 6.71 美元，52 周最高价为 48.94 美元。该公司的市值为 23.2 亿美元，市盈率为-2.30。该公司的 50 日移动平均线为 41.28 美元，200 日移动平均线为 29.58 美元。</p>
<p>Maze Therapeutics（纳斯达克代码：MAZE - 获取免费报告）最近在 11 月 6 日星期四发布了季度财报。公司报告季度每股收益为（0.66 美元），超出分析师一致预期的（0.74 美元）0.08 美元。</p>
<h2>机构投资者对 Maze Therapeutics 的看法</h2>
<p>几家对冲基金最近调整了对 MAZE 的持股。CWM LLC 在第二季度获得了 Maze Therapeutics 的新头寸，价值约 28,000 美元。GF Fund Management CO. LTD.在第四季度购买了 Maze Therapeutics 的新股份，价值约 39,000 美元。Ameritas Investment Partners Inc.在第三季度将其在 Maze Therapeutics 的持股增加了 82.6%。Ameritas Investment Partners Inc.目前持有该公司 1,632 股股票，价值 42,000 美元，此前在上个季度又购买了 738 股。Russell Investments Group Ltd.在第三季度将其在 Maze Therapeutics 的股份增加了 947.8%。Russell Investments Group Ltd.目前持有该公司 1,907 股股票，价值 49,000 美元，此前在此期间又购买了 1,725 股。最后，中国泛海资产管理有限公司在第三季度购买了 Maze Therapeutics 的新头寸，价值约 52,000 美元。</p>
<h2>华尔街分析师预测增长</h2>
<p>几位分析师最近对 MAZE 股票发布了报告。Wall Street Zen 在 1 月 25 日星期日的研究报告中将 Maze Therapeutics 的股票评级从 “卖出” 上调至 “持有”。Weiss Ratings 在 1 月 22 日星期四的研究报告中重申了对 Maze Therapeutics 的 “卖出（d）” 评级。BTIG Research 在 1 月 16 日星期五的报告中将 Maze Therapeutics 的目标价格从 37.00 美元上调至 46.00 美元，并给予该公司 “买入” 评级。Guggenheim 在 12 月 19 日星期五的报告中重申了 “买入” 评级，并设定了 Maze Therapeutics 的 46.00 美元目标价格。最后，富国银行在 12 月 4 日星期四的研究报告中开始覆盖 Maze Therapeutics。他们对该股票给予了 “增持” 评级，并设定了 55.00 美元的价格目标。三位投资分析师对该股票给予了强烈买入评级，七位给予了买入评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Maze Therapeutics 目前的平均评级为 “买入”，平均价格目标为 44.50 美元。</p>
<p><strong>获取我们对 MAZE 的最新分析</strong></p>
<h2>Maze Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Maze Therapeutics, Inc.（纳斯达克：MAZE）是一家临床阶段的生物技术公司，专注于通过利用人类遗传学和基因组学的洞察力发现和开发新型治疗药物。该公司应用先进的数据分析和专有平台，识别具有强大遗传验证的靶点，旨在降低早期药物发现的风险，加速针对严重疾病患者的药物开发。Maze 的方法侧重于将自然发生的人类突变转化为对疾病生物学的更深入理解，强调在进入临床之前验证治疗假设。</p>
<p>自成立以来，Maze 已经组建了一个多元化的项目管道，涵盖代谢、免疫和其他治疗领域。</p>
<h2>特色文章</h2>
<ul>
<li>我们更看好的五只股票超过 Maze Therapeutics</li>
<li>~1.5 万亿美元的 SpaceX IPO：首次公开募股机会</li>
<li>华尔街害怕的黄金图表……</li>
<li>突发：埃隆悄然转变，改变一切</li>
<li>黄金警报</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUFaRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUFaRQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Maze Therapeutics 吗？</h2>
<p>在考虑 Maze Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Maze Therapeutics 并不在名单上。</p>
<p>虽然 Maze Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

MAZE

<p>Maze Therapeutics（纳斯达克代码：MAZE）的高级副总裁 Amy Bachrodt 于 2 月 2 日以每股 46.04 美元的价格出售了 5,000 股，总计 230,200 美元。这次出售使她的持股减少了 27.83%，剩余 12,965 股，估值约为 596,908.60 美元。该交易已向美国证券交易委员会（SEC）披露。Maze Therapeutics 的股票上涨了 0.4%，至 48.14 美元，市值为 23.2 亿美元。分析师对该股票的评级不一，平均目标价为 44.50 美元</p>

<p>Maze Therapeutics, Inc. (NASDAQ:MAZE - Get Free Report) SVP Amy Bachrodt sold 5,000 shares of the firm's stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $46.04, for a total transaction of $230,200.00. Following the transaction, the senior vice president directly owned 12,965 shares in the company, valued at $596,908.60. This represents a 27.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.</p>
<div class="lb-trans"><p>Maze Therapeutics, Inc.（纳斯达克代码：MAZE - 获取免费报告）高级副总裁艾米·巴赫罗特于 2 月 2 日星期一出售了 5,000 股该公司的股票。股票以平均价格 46.04 美元出售，总交易额为 230,200.00 美元。交易后，这位高级副总裁直接持有该公司 12,965 股股票，价值 596,908.60 美元。这代表其持股比例下降了 27.83%。该出售在向美国证券交易委员会（SEC）提交的文件中披露，相关文件可通过 SEC 网站访问。</p>
</div><p>Get <strong>Maze Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Maze Therapeutics</strong> 的提醒：</p>
</div><ul>
<li>Biotech Breakouts: 3 Stocks With Massive Upside Potential</li>
</ul>
<div class="lb-trans"><ul>
<li>生物科技突破：3 只具有巨大上涨潜力的股票</li>
</ul>
</div><p>Amy Bachrodt also recently made the following trade(s):</p>
<div class="lb-trans"><p>艾米·巴赫罗特最近还进行了以下交易：</p>
</div><ul>
<li>On Thursday, January 22nd, Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $45.52, for a total value of $227,600.00.</li>
<li>On Friday, January 2nd, Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $39.15, for a total value of $195,750.00.</li>
<li>On Monday, December 29th, Amy Bachrodt sold 10,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $40.58, for a total value of $405,800.00.</li>
<li>On Tuesday, December 30th, Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $40.08, for a total value of $200,400.00.</li>
</ul>
<div class="lb-trans"><ul>
<li>在 1 月 22 日星期四，艾米·巴赫罗特出售了 5,000 股 Maze Therapeutics 的股票。股票以平均价格 45.52 美元出售，总价值为 227,600.00 美元。</li>
<li>在 1 月 2 日星期五，艾米·巴赫罗特出售了 5,000 股 Maze Therapeutics 的股票。股票以平均价格 39.15 美元出售，总价值为 195,750.00 美元。</li>
<li>在 12 月 29 日星期一，艾米·巴赫罗特出售了 10,000 股 Maze Therapeutics 的股票。股票以平均价格 40.58 美元出售，总价值为 405,800.00 美元。</li>
<li>在 12 月 30 日星期二，艾米·巴赫罗特出售了 5,000 股 Maze Therapeutics 的股票。股票以平均价格 40.08 美元出售，总价值为 200,400.00 美元。</li>
</ul>
</div><h2>Maze Therapeutics Stock Up 0.4%</h2>
<div class="lb-trans"><h2>Maze Therapeutics 股票上涨 0.4%</h2>
</div><p>Shares of MAZE traded up $0.17 during trading hours on Wednesday, hitting $48.14. 588,235 shares of the company were exchanged, compared to its average volume of 434,867. Maze Therapeutics, Inc. has a fifty-two week low of $6.71 and a fifty-two week high of $48.94. The company has a market cap of $2.32 billion and a price-to-earnings ratio of -2.30. The firm's fifty day moving average is $41.28 and its 200 day moving average is $29.58.</p>
<div class="lb-trans"><p>在周三的交易时段，MAZE 的股票上涨了 0.17 美元，达到了 48.14 美元。该公司交易了 588,235 股，相较于其平均交易量 434,867 股。Maze Therapeutics, Inc.的 52 周最低价为 6.71 美元，52 周最高价为 48.94 美元。该公司的市值为 23.2 亿美元，市盈率为-2.30。该公司的 50 日移动平均线为 41.28 美元，200 日移动平均线为 29.58 美元。</p>
</div><p>Maze Therapeutics (NASDAQ:MAZE - Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.66) EPS for the quarter, beating analysts' consensus estimates of ($0.74) by $0.08.</p>
<div class="lb-trans"><p>Maze Therapeutics（纳斯达克代码：MAZE - 获取免费报告）最近在 11 月 6 日星期四发布了季度财报。公司报告季度每股收益为（0.66 美元），超出分析师一致预期的（0.74 美元）0.08 美元。</p>
</div><h2>Institutional Investors Weigh In On Maze Therapeutics</h2>
<div class="lb-trans"><h2>机构投资者对 Maze Therapeutics 的看法</h2>
</div><p>Several hedge funds have recently modified their holdings of MAZE. CWM LLC acquired a new position in Maze Therapeutics in the 2nd quarter worth about $28,000. GF Fund Management CO. LTD. bought a new stake in shares of Maze Therapeutics during the fourth quarter worth about $39,000. Ameritas Investment Partners Inc. grew its holdings in shares of Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company's stock worth $42,000 after purchasing an additional 738 shares during the last quarter. Russell Investments Group Ltd. increased its stake in shares of Maze Therapeutics by 947.8% in the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company's stock valued at $49,000 after buying an additional 1,725 shares during the period. Finally, China Universal Asset Management Co. Ltd. bought a new position in Maze Therapeutics in the 3rd quarter valued at approximately $52,000.</p>
<div class="lb-trans"><p>几家对冲基金最近调整了对 MAZE 的持股。CWM LLC 在第二季度获得了 Maze Therapeutics 的新头寸，价值约 28,000 美元。GF Fund Management CO. LTD.在第四季度购买了 Maze Therapeutics 的新股份，价值约 39,000 美元。Ameritas Investment Partners Inc.在第三季度将其在 Maze Therapeutics 的持股增加了 82.6%。Ameritas Investment Partners Inc.目前持有该公司 1,632 股股票，价值 42,000 美元，此前在上个季度又购买了 738 股。Russell Investments Group Ltd.在第三季度将其在 Maze Therapeutics 的股份增加了 947.8%。Russell Investments Group Ltd.目前持有该公司 1,907 股股票，价值 49,000 美元，此前在此期间又购买了 1,725 股。最后，中国泛海资产管理有限公司在第三季度购买了 Maze Therapeutics 的新头寸，价值约 52,000 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several analysts recently issued reports on MAZE shares. Wall Street Zen upgraded shares of Maze Therapeutics from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Sunday, January 25th. Weiss Ratings restated a &#34;sell (d)&#34; rating on shares of Maze Therapeutics in a research note on Thursday, January 22nd. BTIG Research raised their target price on Maze Therapeutics from $37.00 to $46.00 and gave the company a &#34;buy&#34; rating in a report on Friday, January 16th. Guggenheim reissued a &#34;buy&#34; rating and set a $46.00 price target on shares of Maze Therapeutics in a report on Friday, December 19th. Finally, Wells Fargo &amp; Company initiated coverage on Maze Therapeutics in a research note on Thursday, December 4th. They issued an &#34;overweight&#34; rating and a $55.00 price objective on the stock. Three investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Maze Therapeutics presently has an average rating of &#34;Buy&#34; and an average price target of $44.50.</p>
<div class="lb-trans"><p>几位分析师最近对 MAZE 股票发布了报告。Wall Street Zen 在 1 月 25 日星期日的研究报告中将 Maze Therapeutics 的股票评级从 “卖出” 上调至 “持有”。Weiss Ratings 在 1 月 22 日星期四的研究报告中重申了对 Maze Therapeutics 的 “卖出（d）” 评级。BTIG Research 在 1 月 16 日星期五的报告中将 Maze Therapeutics 的目标价格从 37.00 美元上调至 46.00 美元，并给予该公司 “买入” 评级。Guggenheim 在 12 月 19 日星期五的报告中重申了 “买入” 评级，并设定了 Maze Therapeutics 的 46.00 美元目标价格。最后，富国银行在 12 月 4 日星期四的研究报告中开始覆盖 Maze Therapeutics。他们对该股票给予了 “增持” 评级，并设定了 55.00 美元的价格目标。三位投资分析师对该股票给予了强烈买入评级，七位给予了买入评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，Maze Therapeutics 目前的平均评级为 “买入”，平均价格目标为 44.50 美元。</p>
</div><p><strong>Get Our Latest Analysis on MAZE</strong></p>
<div class="lb-trans"><p><strong>获取我们对 MAZE 的最新分析</strong></p>
</div><h2>Maze Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Maze Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Maze Therapeutics, Inc NASDAQ: MAZE is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze's approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.</p>
<div class="lb-trans"><p>Maze Therapeutics, Inc.（纳斯达克：MAZE）是一家临床阶段的生物技术公司，专注于通过利用人类遗传学和基因组学的洞察力发现和开发新型治疗药物。该公司应用先进的数据分析和专有平台，识别具有强大遗传验证的靶点，旨在降低早期药物发现的风险，加速针对严重疾病患者的药物开发。Maze 的方法侧重于将自然发生的人类突变转化为对疾病生物学的更深入理解，强调在进入临床之前验证治疗假设。</p>
</div><p>Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.</p>
<div class="lb-trans"><p>自成立以来，Maze 已经组建了一个多元化的项目管道，涵盖代谢、免疫和其他治疗领域。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Maze Therapeutics</li>
<li>~$1.5T SpaceX IPO: Pre-IPO Opportunity</li>
<li>The gold chart Wall Street is terrified of…</li>
<li>BREAKING: Elon Makes a Quiet Shift That Changes Everything</li>
<li>GOLD ALERT</li>
<li>What a Former CIA Agent Knows About the Coming Collapse</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Maze Therapeutics</li>
<li>~1.5 万亿美元的 SpaceX IPO：首次公开募股机会</li>
<li>华尔街害怕的黄金图表……</li>
<li>突发：埃隆悄然转变，改变一切</li>
<li>黄金警报</li>
<li>一位前 CIA 特工对即将到来的崩溃的看法</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TUFaRQ" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=MAZE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Maze Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Maze Therapeutics 吗？</h2>
</div><p>Before you consider Maze Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Maze Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maze Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 Maze Therapeutics 并不在名单上。</p>
</div><p>While Maze Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Maze Therapeutics 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Amy Bachrodt 出售了 Maze Therapeutics（NASDAQ:MAZE）5,000 股股票